Presentation of the TOPCHIB study

The ANRS 12417 TOPCHIB study is designed to evaluate the feasibility, efficacy and cost-effectiveness of an antiviral treatment to be delivered to pregnant women with a high viral load or detectable hepatitis B virus e antigen (HBeAg) in a rural region where hepatitis B is highly endemic in Cameroon, in order to prevent mother-to-child transmission (MTCT) of hepatitis B virus (HBV) in a real-life setting. The study will be carried out in the Tokombéré district, where the prevalence of hepatitis B is around 20% and where antiviral treatment of pregnant women has long been successfully introduced to prevent MTCT of HIV.